{"gene":"POU1F1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1988,"finding":"GHF-1 (POU1F1) is a homeobox-containing protein; the homeodomain region near its C-terminus functions as its DNA-binding domain, demonstrated by DNase I footprinting with bacterially expressed GHF-1 fusion protein.","method":"cDNA cloning, sequence analysis, DNase I footprinting with bacterially expressed fusion protein","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro biochemical reconstitution (footprinting with recombinant protein), foundational study replicated widely","pmids":["2902927"],"is_preprint":false},{"year":1989,"finding":"The GHF-1/POU1F1 homeodomain is sufficient for sequence-specific DNA binding; the POU-specific domain stimulates DNA binding but does not contact DNA directly; transcriptional activation is mediated by a separate hydroxylated amino-acid-rich domain.","method":"Domain deletion/truncation analysis, in vitro transcription, DNA-binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple domain dissection experiments with functional readouts in a single rigorous study","pmids":["2574416"],"is_preprint":false},{"year":1989,"finding":"Purified GHF-1/POU1F1 (33 kDa) binds to and activates the GH promoter but does not recognize the prolactin (Prl) promoter; a distinct factor in the same extracts binds the Prl promoter.","method":"Protein purification, gel-shift assay, in vitro transcription, immunoblotting","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — purified native protein used in multiple in vitro assays","pmids":["2563596"],"is_preprint":false},{"year":1988,"finding":"Extinction of GH expression in fibroblast × pituitary cell hybrids occurs via repression of GHF-1/POU1F1 protein and mRNA, not via a direct repressor of the GH promoter.","method":"Somatic cell hybridization, in vivo transfection, in vitro transcription, DNase I footprinting, immunoblotting","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, epistasis-like genetic experiment with clear mechanism","pmids":["3167985"],"is_preprint":false},{"year":1990,"finding":"POU1F1/Pit-1 binds to and activates cell-specific elements in both the GH and PRL gene promoters; 31 and 33 kDa nuclear proteins recognized by a Pit-1/GHF-1 antibody bind these elements in pituitary cells; cotransfection of RSV-Pit-1/GHF-1 into non-pituitary HeLa cells reconstitutes activation of both promoters.","method":"Protein-DNA binding assays, cotransfection/reporter assay, immunoblotting with Pit-1 antibody","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding and functional reconstitution in non-pituitary cells, multiple orthogonal methods","pmids":["2284007"],"is_preprint":false},{"year":1990,"finding":"Sp1 binding to its site on the human GH promoter is mutually exclusive with GHF-1 binding to its distal site (demonstrated by DNase I footprinting), and Sp1 can partially compensate for low GHF-1 concentrations in stimulating transcription.","method":"DNase I footprinting, cell-free transcription assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro assays but single lab, limited functional follow-up","pmids":["2181288"],"is_preprint":false},{"year":1991,"finding":"POU1F1/Pit-1 (or a closely related protein) mediates TRH responsiveness of the human TSHβ (TSHB) gene via a binding site at -128 to -92 bp; demonstrated by DNase I footprinting with thyrotropic tumor extract and transfection studies with an N-terminal deletion of Pit-1/GHF-1.","method":"DNase I footprinting, deletion analysis, transient transfection with reporter gene","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DNase I footprinting plus functional transfection, single lab","pmids":["1901656"],"is_preprint":false},{"year":1993,"finding":"GHF-1/POU1F1 is required for generation of somatotropes and lactotropes and for GH and PRL gene expression during pituitary development; immortalization of GHF-1-expressing progenitors that lack GH/PRL results in dwarfism, and an early-acting GHF-1 transcriptional enhancer was identified in this progenitor context.","method":"Transgenic mouse model (GHF-1 promoter driving SV40 T-antigen), cell line derivation, functional enhancer assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic loss-of-function with clear developmental phenotype, replicated in derived cell lines","pmids":["8096199"],"is_preprint":false},{"year":1993,"finding":"POU1F1/Pit-1 binds to three A-T-rich regions (TSH A, B, C) in the 5'-flanking region of the rat TSHβ gene; TSH A and TSH C each confer TRH-stimulated and/or enhanced basal activity to a heterologous promoter, and all three elements bind in vitro-translated Pit-1 with defined affinities.","method":"Gel mobility shift assay with antibody supershift, transient transfection reporter assay, in vitro translated protein binding","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding with recombinant protein plus functional reporter assay, single lab","pmids":["8364038"],"is_preprint":false},{"year":1995,"finding":"GHF-1/POU1F1 undergoes M-phase-specific phosphorylation at Thr-220 (within the N-terminal arm of the homeodomain) by a novel mitotic kinase activity distinct from Cdc2 or PKA, transiently inhibiting its DNA-binding activity during mitosis; PKA does not phosphorylate this inhibitory site in living cells.","method":"In vivo phosphorylation analysis, in vitro kinase assays, site-directed mutagenesis, cell synchronization, DNA-binding assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay combined with mutagenesis and DNA-binding readout, multiple methods","pmids":["8524234"],"is_preprint":false},{"year":1995,"finding":"GHF-1/POU1F1 and PKA synergistically activate the rat PRL promoter via the FP I site; GHF-1 is necessary but not sufficient for the full PKA response, which also requires a GHF-1-independent ubiquitous factor acting at FP I.","method":"Cotransfection reconstitution assay in HeLa cells with expression vectors, site-specific mutagenesis, luciferase reporter","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution in non-pituitary cells with site-directed mutations, single lab","pmids":["7659093"],"is_preprint":false},{"year":1995,"finding":"GHRH increases GHF-1/POU1F1 mRNA levels via a transcriptional mechanism not requiring new protein synthesis; IGF-1 inhibits basal GHF-1 mRNA and blocks GHRH induction; somatostatin has no effect.","method":"Primary anterior pituitary cell culture, Northern blotting, actinomycin D and cycloheximide treatments, pharmacological activation of second messengers","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with transcription inhibitors, multiple hormone treatments, single lab","pmids":["7649093"],"is_preprint":false},{"year":1995,"finding":"Retinoic acid induces GHF-1/POU1F1 mRNA and protein expression in pituitary cell lines via sequences between -400 and -90 bp of the GHF-1/Pit-1 promoter containing two CREs, both of which are required; T3 decreases GHF-1 mRNA and promoter activity in GH4C1 cells and blocks RA stimulation.","method":"Northern blotting, Western blotting, gel retardation assay, promoter-reporter transfection with deletion constructs","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (Northern, Western, EMSA, reporter), single lab","pmids":["7588287"],"is_preprint":false},{"year":1995,"finding":"T3 represses GHF-1/POU1F1 gene expression by transcriptional interference with CRE-containing promoter elements (bp -90 to -200), not through a canonical TRE, and also interferes with GHF-1 binding to a positive autoregulatory element at bp -45 to -63.","method":"Promoter-reporter transfection with deletion constructs, in vitro DNA-binding assay, RT-PCR/Northern","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion mapping with functional reporter plus in vitro binding, single lab","pmids":["7565785"],"is_preprint":false},{"year":1996,"finding":"POU1F1/GHF-1 functions as a cell-specific integrator of Ras signaling by forming a composite binding site with Ets-1 at positions -217 to -190 of the rat PRL promoter; both Ets-1 and GHF-1 binding sites are required for Ras/Raf activation; the composite element confers Ras responsiveness when inserted into the GH promoter.","method":"Site-directed mutagenesis of promoter, luciferase reporter assay, EMSA, insertion of composite element into heterologous promoter","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (mutagenesis, reporter, EMSA, element transfer), functional epistasis","pmids":["8798730"],"is_preprint":false},{"year":1998,"finding":"GHF-1/POU1F1 physically interacts with RXR (strong), RAR (weak), and TR (weak) via in vitro GST pull-down; GHF-1 and TR/RXR or RAR/RXR heterodimers form a ternary complex with the GH promoter fragment, and GHF-1 increases receptor binding to the promoter under limiting conditions.","method":"GST pull-down (in vitro binding), EMSA (ternary complex), reporter assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GST pull-down plus EMSA ternary complex, single lab","pmids":["9737723"],"is_preprint":false},{"year":1998,"finding":"In pituitary cells, GHF-1/POU1F1 converts T3/RA receptor-mediated repression into ligand-dependent activation of the GH promoter; a truncated T3 receptor lacking N-terminus and DNA-binding domain still activates the GH promoter in the presence of GHF-1 and RXR, indicating protein-protein interaction is sufficient.","method":"Transient transfection reporter assay in HeLa cells with/without GHF-1, GH promoter activity measurement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution with domain-deleted receptors, single lab","pmids":["9765286"],"is_preprint":false},{"year":1999,"finding":"VDR and GHF-1/Pit-1 synergistically activate the PRL promoter; coactivators CBP and SRC-1 enhance VDR-mediated activation via the AF-2 domain; CBP also enhances GHF-1-mediated activation of the PRL promoter.","method":"Transient transfection reporter assay in HeLa cells, cotransfection with VDR, GHF-1, SRC-1, and CBP expression vectors, AF-2 mutant analysis","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reconstitution in non-pituitary cells with multiple cofactors, single lab","pmids":["10406465"],"is_preprint":false},{"year":1999,"finding":"POU1F1/Pit-1 directly binds the serum response element (SRE) in the c-fos promoter (albeit with lower affinity than its cognate site) and activates c-fos transcription in a phosphorylation-dependent manner; Pit-1 phosphorylation sites are required for c-fos promoter activity but not for hormonal gene regulation.","method":"Gel shift analysis, overexpression in PC12 cells, antisense-mediated knockdown in GH3 cells, reporter assay with mutant Pit-1 phosphorylation sites","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus loss-of-function knockdown plus reporter assay, single lab","pmids":["10319324"],"is_preprint":false},{"year":1999,"finding":"POU1F1/Pit-1 binds A/T-rich sequences within a 203-bp enhancer element of the human GH locus control region (LCR) HSII region and is required for enhancer activity in pituitary cells in culture and in transgenic mice.","method":"EMSA (competition and antibody supershift with recombinant protein), deletion analysis, promoter-reporter transfection, transgenic mouse reporter","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding with recombinant protein, functional validation both in culture and in vivo (transgenic mice)","pmids":["10446901"],"is_preprint":false},{"year":2005,"finding":"POU1F1 mutation E230K reduces transactivation but not DNA-binding affinity; R172Q reduces both DNA binding and transactivation; ins778A abolishes DNA binding and reduces transactivation — demonstrating mutation-specific functional defects in the context of CPHD.","method":"Functional studies: transactivation reporter assay, DNA-binding affinity assay (EMSA or similar)","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal functional assays (DNA binding + transactivation) per mutation, single lab","pmids":["15928241"],"is_preprint":false},{"year":2005,"finding":"LHX4 binds to a human-specific element in the POU1F1 upstream regulatory sequence and activates POU1F1 transcription; mutant LHX4 proteins from CPHD patients fail to bind and activate the POU1F1 regulatory sequence but do not act as dominant negatives over normal LHX4.","method":"Recombinant protein expression in CHO cells, DNA-binding assay, reporter/transactivation assay","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding and transactivation assays, single lab, single cell system","pmids":["15998782"],"is_preprint":false},{"year":2008,"finding":"OTX2 binds to target sequences within the POU1F1 promoter and markedly transactivates it (~19-fold); a frameshift OTX2 mutation retaining the homeodomain but losing the transactivation domain barely retains this activity with no dominant-negative effect.","method":"Transfection reporter (luciferase) assay, nuclear localization assay, OTX2 wild-type vs. mutant comparison","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay with mutant comparison, single lab","pmids":["18628516"],"is_preprint":false},{"year":2008,"finding":"POU1F1 mutation S179R (in the POU-specific domain) abolishes interaction with coactivator CBP on the PRL promoter (but not with LHX3) and markedly reduces DNA binding and transactivation, with normal nuclear accumulation.","method":"Transactivation reporter assay, EMSA (DNA binding), nuclear accumulation assay, functional interaction studies in alphaT3 cells","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (EMSA, reporter, cofactor interaction), single lab","pmids":["16968807"],"is_preprint":false},{"year":2008,"finding":"POU1F1 proliferative response to GHRH is cell-type specific and requires Pit-1/GHF-1 expression; Pit-1 is needed for downstream GHRH receptor signaling effects on cell proliferation (p27 degradation), demonstrated by Pit-1 siRNA knockdown in GH3-GHRHR cells and by exogenous Pit-1 expression in CHO-4 cells.","method":"siRNA knockdown, overexpression, cell proliferation assays, Western blotting for cell cycle regulators","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal loss- and gain-of-function in two cell types, single lab","pmids":["17941086"],"is_preprint":false},{"year":2009,"finding":"POU1F1 binds directly to a site near the Syt1 (synaptotagmin I) initiation exon in GH3 pituitary cells (ChIP, in vitro binding), and POU1F1 knockdown reduces endogenous Syt1 mRNA; luciferase reporter assays confirm a POU1F1-regulated internal Syt1 promoter.","method":"Chromatin immunoprecipitation (ChIP), shRNA knockdown, in vitro DNA binding, luciferase reporter transfection","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus knockdown plus reporter assay, multiple methods, single lab","pmids":["19608642"],"is_preprint":false},{"year":2012,"finding":"IGF-1 inhibits GH gene expression by disrupting the POU1F1/CBP complex at the GH promoter; IGF-1 receptor signaling prevents CBP binding to the GH promoter (shown by ChIP), and a CBP S436A phosphorylation-dead mutant abolishes IGF-1 inhibition, elevating serum GH in knock-in mice.","method":"ChIP assay, luciferase reporter, CBP mutant (S436A) knock-in mouse model, serum GH/GHRH stimulation assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, mutagenesis, and in vivo knock-in mouse validation — multiple orthogonal methods","pmids":["22890843"],"is_preprint":false},{"year":2012,"finding":"POU1F1 directly binds multiple sites at the HSII region of the hGH LCR, confers robust POU1F1-dependent activation of hGH-N in a minichromosome model, and is required for POU1F1-dependent histone acetylation and methylation throughout the LCR/hGH-N domain; one binding site maps to the 3' UTR of a primate-specific LINE-1 retrotransposon.","method":"Minichromosome reporter system, in vitro DNA binding, ChIP for histone modifications, transfection assays","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel chromatin system with multiple binding and ChIP experiments, single lab","pmids":["22094313"],"is_preprint":false},{"year":2015,"finding":"POU1F1 Pro76Leu mutation (in the transactivation domain) selectively alters DNA-binding affinity at hGH-LCR and hGH1 sites (but not PRL sites), enhances interactions with cofactors PITX1, LHX3a, and ELK1 (by Co-IP), and causes dramatic loss of protein expression in homozygous knock-in mice despite normal mRNA levels.","method":"Bandshift (EMSA) assay, Co-immunoprecipitation, knock-in mouse model, immunoblotting","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (EMSA, Co-IP, in vivo knock-in), single lab but rigorous","pmids":["26612202"],"is_preprint":false},{"year":2015,"finding":"ERK (downstream of FGFR2) directly interacts with and phosphorylates POU1F1, increasing POU1F1 binding to the Mre11 promoter and repressing Mre11 expression, thereby decreasing double-strand break repair in breast cancer cells.","method":"Co-immunoprecipitation, phosphorylation assay, ChIP on Mre11 promoter, reporter assay, shRNA knockdown","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus reporter assay, single lab","pmids":["25788520"],"is_preprint":false},{"year":2019,"finding":"POU1F1 (Pit-1) in breast tumor cells drives recruitment and M2 polarization of macrophages via transcriptional regulation of CXCL12 secretion; TAMs in turn promote tumor growth, angiogenesis, and lung metastasis.","method":"In vitro co-culture, zebrafish and mouse xenograft models, CXCL12 measurement, flow cytometry for macrophage markers, shRNA knockdown of POU1F1","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in multiple in vivo models with mechanistic pathway (CXCL12/CXCR4), single lab","pmids":["31292963"],"is_preprint":false},{"year":2020,"finding":"POU1F1 mediates ADTRP-induced transcription of TFPI by binding to a 50-bp ADTRP-response element (-806 to -756 bp upstream of TFPI TSS); knockdown of POU1F1 abolishes ADTRP-mediated TFPI transcription; direct binding confirmed by ChIP and EMSA.","method":"Luciferase reporter assay (large/small deletions), ChIP, EMSA, siRNA knockdown","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus EMSA plus reporter plus knockdown, multiple orthogonal methods, single lab","pmids":["32445923"],"is_preprint":false},{"year":2021,"finding":"POU1F1 transcriptionally regulates the LDHA gene in breast cancer cells; POU1F1 overexpression increases LDHA expression and lactate production, promoting glycolytic reprogramming; LDHA knockdown in POU1F1-overexpressing cells reduces tumor volume and [18F]FDG uptake in xenograft mice.","method":"shRNA knockdown, overexpression, luciferase reporter, xenograft mouse model with PET imaging, human primary cancer cell cultures","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter plus in vivo xenograft validation, multiple methods, single lab","pmids":["33714987"],"is_preprint":false},{"year":2021,"finding":"HMGA1B/2 transcriptionally activates POU1F1 in gastric cancer; POU1F1 in turn promotes CXCL12/CXCR4-dependent macrophage polarization; GST pull-down and Co-IP confirmed physical interaction between HMGA1B/2 and POU1F1; ChIP and dual luciferase assays confirmed HMGA1B/2 transcriptional regulation of POU1F1.","method":"GST pull-down, Co-immunoprecipitation, ChIP, dual luciferase reporter assay, xenograft mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (GST pull-down, Co-IP, ChIP, reporter), single lab","pmids":["33927188"],"is_preprint":false},{"year":2021,"finding":"The stem cell RNA-binding protein Musashi1 directly binds the Pou1f1 mRNA 3' UTR and exerts translational repression of POU1F1 in female somatotropes; leptin signaling is required to relieve this repression; Musashi immunoprecipitation from whole pituitary co-purifies Pou1f1 mRNA.","method":"RNA immunoprecipitation, translational reporter assay, Cre-LoxP Lepr-null somatotrope purification, immunocytochemistry, single-cell RNA-seq","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA IP plus functional reporter plus genetic model, multiple methods, single lab","pmids":["33373440"],"is_preprint":false},{"year":2021,"finding":"Heterozygous missense POU1F1 variants that affect only the POU1F1 beta isoform retain repressor activity and shift splicing to favor the beta isoform, causing dominant-negative loss of function; identified by high-throughput splicing reporter assay testing 1,070 SNVs.","method":"High-throughput splicing reporter assay (1,070 variants), functional repressor activity assay, clinical co-segregation in multiple families","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — large-scale systematic splicing assay plus functional validation, replicated across multiple unrelated families","pmids":["34270938"],"is_preprint":false},{"year":2021,"finding":"A POU1F1 intronic variant (c.143-69T>G in intron 1 of PIT-1α) shifts splicing to produce exclusively the PIT-1β transcript; the PIT-1β-Ile51Ser mutant protein represses PIT-1α transcriptional activity and abolishes transactivation of the rat PRL promoter in GH3 cells, causing CPHD.","method":"Gene splicing experiments, luciferase reporter assay, lymphocyte mRNA expression analysis","journal":"European journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — splicing assay plus functional reporter in pituitary cells, single lab","pmids":["33886498"],"is_preprint":false},{"year":2022,"finding":"The intronic Pou1f1 variant c.143-83A>G disrupts a branch site in the pre-mRNA, shifting splicing to decrease the alpha isoform, increase the beta isoform, and produce an exon-skipped transcript; homozygous knock-in mice show pituitary hypoplasia, somatotroph reduction, dwarfism, and IGF-1/T4 deficiency.","method":"Knock-in mouse model (CRISPR/genome engineering), RNA-seq, RT-PCR, immunohistochemistry, splicing analysis in cultured cells","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knock-in model with RNA-seq, histology, and cell-based splicing assays confirming mechanism","pmids":["36427334"],"is_preprint":false},{"year":2016,"finding":"Leptin signaling to somatotropes is required to maintain POU1F1 protein levels and all POU1F1-dependent hormones (GH, PRL, TSH); reduction is sex-dependent (occurs in females but not males for TSH and PRL), demonstrating a tropic role for leptin in controlling POU1F1-dependent cell lineages.","method":"Cre-LoxP conditional Lepr knockout in somatotropes, FACS-purified cell populations, enzyme immunoassays, qPCR","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional knockout with purified somatotropes, functional hormone measurements, single lab","pmids":["27571135"],"is_preprint":false},{"year":2001,"finding":"POU1F1 W193R missense mutation (in the fourth alpha-helix of the POU-specific domain) causes a ~500-fold reduction in DNA binding and transcriptional activation; a frameshift (747delA) removes the entire DNA recognition helix of the homeodomain, producing a nonfunctional protein.","method":"DNA-binding assay, transactivation reporter assay, cell transfection","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative DNA-binding plus reporter assay for two mutations, single lab","pmids":["11297581"],"is_preprint":false},{"year":2023,"finding":"Genetic epistasis between Pou1f1 and Six3 in mice: Six3 heterozygotes have pituitary dysmorphology; Six3+/-; Pou1f1+/dw double heterozygotes have a pronounced pituitary phenotype including pituitary growth through the palate, supporting digenic pituitary disease.","method":"Genetically engineered double-heterozygous mice, pituitary histology, phenotypic analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with defined phenotype, single lab but clear digenic interaction","pmids":["35951005"],"is_preprint":false}],"current_model":"POU1F1 (GHF-1/Pit-1) is a pituitary-specific POU-homeodomain transcription factor whose homeodomain mediates sequence-specific DNA binding (stimulated by the POU-specific domain), while a separate hydroxylated amino-acid-rich domain drives transcriptional activation; it directly activates GH, PRL, and TSHβ gene promoters, autoregulates its own promoter, and is required for the specification and expansion of somatotrope, lactotrope, and thyrotrope lineages; its activity is regulated by M-phase-specific phosphorylation at Thr-220 that transiently inhibits DNA binding, by IGF-1 receptor signaling that disrupts its interaction with the coactivator CBP, by Musashi1-mediated translational repression of its mRNA (reversed by leptin), and by alternative splicing that produces a repressive beta isoform; it integrates upstream signals (GHRH/cAMP/Ras via Ets-1, thyroid hormone and retinoic acid receptors via physical interaction, LHX4 and OTX2 upstream activation) and in cancer contexts transcriptionally activates LDHA and CXCL12 to promote metabolic reprogramming and macrophage polarization."},"narrative":{"mechanistic_narrative":"POU1F1 (GHF-1/Pit-1) is a pituitary-specific POU-homeodomain transcription factor that specifies and expands the somatotrope, lactotrope, and thyrotrope lineages and directly drives their hormone gene programs [PMID:8096199]. Its C-terminal homeodomain is sufficient for sequence-specific DNA binding while the POU-specific domain stimulates that binding without contacting DNA directly, and transcriptional activation is carried by a separate hydroxylated amino-acid-rich domain [PMID:2902927, PMID:2574416]. The factor binds and activates cell-specific elements of the GH and PRL promoters — reconstituting their activation when introduced into non-pituitary cells [PMID:2563596, PMID:2284007] — and binds A-T-rich elements of the TSHβ gene to confer TRH responsiveness [PMID:1901656, PMID:8364038]. At the human GH locus it occupies multiple sites in the locus control region HSII enhancer and is required for POU1F1-dependent histone acetylation/methylation and high-level hGH-N expression [PMID:10446901, PMID:22094313]. POU1F1 also acts as a signal integrator: it forms a composite element with Ets-1 to confer Ras responsiveness [PMID:8798730], cooperates with nuclear hormone receptors (RXR/RAR/TR, VDR) through direct interaction and ternary-complex formation on target promoters [PMID:9737723, PMID:9765286, PMID:10406465], and recruits the coactivator CBP, an interaction disrupted by IGF-1 receptor signaling to inhibit GH expression [PMID:16968807, PMID:22890843]. Its activity is gated by M-phase-specific phosphorylation at Thr-220 that transiently inhibits DNA binding [PMID:8524234], by Musashi1-mediated translational repression of its mRNA that is relieved by leptin signaling [PMID:33373440, PMID:27571135], and by alternative splicing that generates a repressive beta isoform [PMID:34270938, PMID:33886498]. Loss-of-function and dominant-negative POU1F1 variants — affecting DNA binding, transactivation, cofactor interaction, or splicing — cause combined pituitary hormone deficiency [PMID:15928241, PMID:16968807, PMID:34270938, PMID:36427334, PMID:11297581]. In cancer contexts POU1F1 transcriptionally activates LDHA to drive glycolytic reprogramming and CXCL12 to recruit and M2-polarize macrophages, promoting tumor growth and metastasis [PMID:31292963, PMID:33714987].","teleology":[{"year":1989,"claim":"Establishing how DNA recognition and activation are partitioned within the protein defined POU1F1 as a modular POU-homeodomain factor.","evidence":"cDNA cloning, DNase I footprinting with recombinant protein, and domain deletion/truncation with in vitro transcription readouts","pmids":["2902927","2574416"],"confidence":"High","gaps":["No structural model of the DNA-bound complex","Role of the POU-specific domain in stimulating binding defined functionally but not structurally"]},{"year":1990,"claim":"Demonstrating direct binding and reconstituted activation of GH and PRL promoters established POU1F1 as the cell-specific activator of these hormone genes.","evidence":"Protein purification, gel-shift, in vitro transcription, and cotransfection reconstitution in non-pituitary HeLa cells","pmids":["2563596","2284007"],"confidence":"High","gaps":["Early purified protein did not bind PRL promoter, later resolved by reconstitution","Did not address chromatin context of native loci"]},{"year":1993,"claim":"Resolving whether POU1F1 is required for lineage formation versus only hormone transcription showed it is needed for somatotrope/lactotrope generation in vivo.","evidence":"Transgenic mouse with GHF-1 promoter driving SV40 T-antigen, derived progenitor cell lines, and enhancer assay","pmids":["8096199"],"confidence":"High","gaps":["Did not define the upstream specification cascade","Mechanism of lineage expansion versus maintenance not separated"]},{"year":1993,"claim":"Mapping A-T-rich TSHβ elements extended POU1F1's direct target repertoire to thyrotrope hormone genes and TRH responsiveness.","evidence":"Gel-shift with antibody supershift, in vitro-translated protein binding, and transfection reporter assays on rat/human TSHβ","pmids":["1901656","8364038"],"confidence":"Medium","gaps":["TRH signaling link to POU1F1 occupancy not mechanistically resolved","Relative contributions of the three elements in vivo unknown"]},{"year":1996,"claim":"Showing POU1F1 forms a composite Ets-1 element established it as a cell-specific integrator of Ras/Raf signaling.","evidence":"Promoter mutagenesis, luciferase reporter, EMSA, and transfer of the composite element to a heterologous promoter","pmids":["8798730"],"confidence":"High","gaps":["Direct POU1F1-Ets-1 contact not biochemically mapped","Other Ras-responsive POU1F1 targets not catalogued"]},{"year":1998,"claim":"Demonstrating physical interaction with nuclear hormone receptors explained how POU1F1 converts receptor-mediated repression into ligand-dependent GH activation.","evidence":"GST pull-down, ternary-complex EMSA, and reporter assays with domain-deleted receptors in pituitary and HeLa cells","pmids":["9737723","9765286"],"confidence":"Medium","gaps":["Interaction surfaces not mapped at residue level","In vivo relevance to physiological GH regulation not tested"]},{"year":1995,"claim":"Identifying M-phase Thr-220 phosphorylation revealed cell-cycle gating of POU1F1 DNA binding by a non-Cdc2/non-PKA mitotic kinase.","evidence":"In vivo and in vitro kinase assays, site-directed mutagenesis, cell synchronization, and DNA-binding readouts","pmids":["8524234"],"confidence":"High","gaps":["Identity of the mitotic kinase unknown","Consequence for hormone gene output across the cycle not quantified"]},{"year":2012,"claim":"Tracing IGF-1 inhibition to disruption of the POU1F1/CBP complex provided a coactivator-level mechanism for negative feedback on GH.","evidence":"ChIP, luciferase reporter, and a CBP S436A phospho-dead knock-in mouse with serum GH measurement","pmids":["22890843","16968807"],"confidence":"High","gaps":["Kinase phosphorylating CBP S436 downstream of IGF-1R not defined here","Whether other coactivators substitute is unknown"]},{"year":2008,"claim":"Identifying LHX4 and OTX2 as direct activators of the POU1F1 promoter placed POU1F1 within an upstream transcriptional hierarchy of pituitary development.","evidence":"Recombinant binding and transactivation reporter assays comparing wild-type versus CPHD-patient mutant LHX4/OTX2","pmids":["15998782","18628516"],"confidence":"Medium","gaps":["Combinatorial regulation of the POU1F1 promoter not resolved","Some regulatory elements are human-specific, limiting cross-species inference"]},{"year":2021,"claim":"Showing Musashi1 translationally represses Pou1f1 mRNA, reversibly via leptin, revealed a post-transcriptional and metabolic control layer over POU1F1 abundance.","evidence":"RNA immunoprecipitation, translational reporter, leptin receptor conditional knockout, and somatotrope purification","pmids":["33373440","27571135"],"confidence":"Medium","gaps":["Sex-dependence of leptin control mechanistically unexplained","Other RBPs acting on Pou1f1 mRNA not surveyed"]},{"year":2022,"claim":"Systematic splicing variant assays and knock-in models established that shifting the alpha/beta isoform balance toward a repressive beta isoform causes dominant-negative CPHD.","evidence":"High-throughput splicing reporter (1,070 SNVs), repressor activity assays, multi-family co-segregation, and CRISPR knock-in mice","pmids":["34270938","33886498","36427334"],"confidence":"High","gaps":["Beta-isoform target genes and repression mechanism not fully defined","Tissue-specific splicing regulators controlling the alpha/beta ratio unknown"]},{"year":2021,"claim":"Defining POU1F1 targets in tumor cells (LDHA, CXCL12, Mre11) showed it drives metabolic reprogramming, immune microenvironment remodeling, and altered DNA repair outside the pituitary.","evidence":"shRNA/overexpression, ChIP, reporter assays, Co-IP with ERK/HMGA, and xenograft/zebrafish models with PET imaging and macrophage profiling","pmids":["33714987","31292963","25788520","33927188"],"confidence":"Medium","gaps":["What activates POU1F1 in non-pituitary tumors only partially defined (HMGA1B/2, FGFR2/ERK)","Direct versus indirect status of some cancer targets not fully separated"]},{"year":null,"claim":"How the diverse POU1F1 control layers — mitotic phosphorylation, coactivator switching, translational repression, and alpha/beta splicing — are coordinated in vivo to set lineage-specific hormone output remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated model linking the regulatory inputs","Identity of the M-phase kinase and the beta-isoform repressive program still open","Structural basis of DNA and cofactor recognition not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,4,7,14,32]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,8,19,39]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,23]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,4,7,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,21,22,40]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,26,29]}],"complexes":[],"partners":["CREBBP","ETS1","RXR","TR","VDR","LHX3","PITX1","ELK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28069","full_name":"Pituitary-specific positive transcription factor 1","aliases":["Growth hormone factor 1","GHF-1"],"length_aa":291,"mass_kda":32.9,"function":"Transcription factor involved in the specification of the lactotrope, somatotrope, and thyrotrope phenotypes in the developing anterior pituitary. Specifically binds to the consensus sequence 5'-TAAAT-3'. Activates growth hormone and prolactin genes (PubMed:22010633, PubMed:26612202)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P28069/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/POU1F1","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/POU1F1","total_profiled":1310},"omim":[{"mim_id":"618160","title":"PITUITARY HORMONE DEFICIENCY, COMBINED OR ISOLATED, 7; CPHD7","url":"https://www.omim.org/entry/618160"},{"mim_id":"617686","title":"PITUITARY ADENOMA 3, MULTIPLE TYPES; PITA3","url":"https://www.omim.org/entry/617686"},{"mim_id":"613986","title":"PITUITARY HORMONE DEFICIENCY, COMBINED, 6; CPHD6","url":"https://www.omim.org/entry/613986"},{"mim_id":"613038","title":"PITUITARY HORMONE DEFICIENCY, COMBINED OR ISOLATED, 1; CPHD1","url":"https://www.omim.org/entry/613038"},{"mim_id":"610125","title":"MICROPHTHALMIA, SYNDROMIC 5; MCOPS5","url":"https://www.omim.org/entry/610125"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"pituitary gland","ntpm":55.4}],"url":"https://www.proteinatlas.org/search/POU1F1"},"hgnc":{"alias_symbol":["GHF-1","POU1F1a","PIT-1"],"prev_symbol":["PIT1"]},"alphafold":{"accession":"P28069","domains":[{"cath_id":"1.10.260.40","chopping":"126-201","consensus_level":"high","plddt":92.5359,"start":126,"end":201},{"cath_id":"1.10.10.60","chopping":"222-286","consensus_level":"high","plddt":84.7618,"start":222,"end":286}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28069","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28069-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28069-F1-predicted_aligned_error_v6.png","plddt_mean":67.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=POU1F1","jax_strain_url":"https://www.jax.org/strain/search?query=POU1F1"},"sequence":{"accession":"P28069","fasta_url":"https://rest.uniprot.org/uniprotkb/P28069.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28069/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28069"}},"corpus_meta":[{"pmid":"2902927","id":"PMC_2902927","title":"The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein.","date":"1988","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2902927","citation_count":692,"is_preprint":false},{"pmid":"2574416","id":"PMC_2574416","title":"Dissection of functional domains of the pituitary-specific transcription factor GHF-1.","date":"1989","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2574416","citation_count":218,"is_preprint":false},{"pmid":"1690079","id":"PMC_1690079","title":"Expression of GHF-1 protein in mouse pituitaries correlates both temporally and spatially with the onset of growth hormone gene activity.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1690079","citation_count":212,"is_preprint":false},{"pmid":"1901656","id":"PMC_1901656","title":"Thyrotropin-releasing hormone regulation of human TSHB expression: role of a pituitary-specific transcription factor (Pit-1/GHF-1) and potential interaction with a thyroid hormone-inhibitory element.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1901656","citation_count":125,"is_preprint":false},{"pmid":"2284007","id":"PMC_2284007","title":"The homeodomain protein, Pit-1/GHF-1, is capable of binding to and activating cell-specific elements of both the growth hormone and prolactin gene promoters.","date":"1990","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2284007","citation_count":124,"is_preprint":false},{"pmid":"8096199","id":"PMC_8096199","title":"GHF-1-promoter-targeted immortalization of a somatotropic progenitor cell results in dwarfism in transgenic mice.","date":"1993","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8096199","citation_count":121,"is_preprint":false},{"pmid":"2563596","id":"PMC_2563596","title":"Purification of growth hormone-specific transcription factor GHF-1 containing homeobox.","date":"1989","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2563596","citation_count":105,"is_preprint":false},{"pmid":"3167985","id":"PMC_3167985","title":"Extinction of growth hormone expression in somatic cell hybrids involves repression of the specific trans-activator GHF-1.","date":"1988","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3167985","citation_count":83,"is_preprint":false},{"pmid":"15928241","id":"PMC_15928241","title":"Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15928241","citation_count":80,"is_preprint":false},{"pmid":"8458380","id":"PMC_8458380","title":"The transcription factor Pit-1/GHF-1 is expressed in hemopoietic and lymphoid tissues.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8458380","citation_count":76,"is_preprint":false},{"pmid":"8524234","id":"PMC_8524234","title":"M-phase-specific phosphorylation of the POU transcription factor GHF-1 by a cell cycle-regulated protein kinase inhibits DNA binding.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8524234","citation_count":59,"is_preprint":false},{"pmid":"18628516","id":"PMC_18628516","title":"OTX2 mutation in a patient with anophthalmia, short stature, and partial growth hormone deficiency: functional studies using the IRBP, HESX1, and POU1F1 promoters.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18628516","citation_count":58,"is_preprint":false},{"pmid":"7649093","id":"PMC_7649093","title":"Regulation of the pituitary-specific transcription factor GHF-1/Pit-1 messenger ribonucleic acid levels by growth hormone-secretagogues in rat anterior pituitary cells in monolayer culture.","date":"1995","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7649093","citation_count":55,"is_preprint":false},{"pmid":"8798730","id":"PMC_8798730","title":"GHF-1/Pit-1 functions as a cell-specific integrator of Ras signaling by targeting the Ras pathway to a composite Ets-1/GHF-1 response element.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798730","citation_count":54,"is_preprint":false},{"pmid":"33927188","id":"PMC_33927188","title":"HMGA1B/2 transcriptionally activated-POU1F1 facilitates gastric carcinoma metastasis via CXCL12/CXCR4 axis-mediated macrophage polarization.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33927188","citation_count":50,"is_preprint":false},{"pmid":"8297469","id":"PMC_8297469","title":"Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours.","date":"1993","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8297469","citation_count":50,"is_preprint":false},{"pmid":"2181288","id":"PMC_2181288","title":"Sp1 can displace GHF-1 from its distal binding site and stimulate transcription from the growth hormone gene promoter.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2181288","citation_count":47,"is_preprint":false},{"pmid":"22890843","id":"PMC_22890843","title":"Insulin-like growth factor 1 mediates negative feedback to somatotroph GH expression via POU1F1/CREB binding protein interactions.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22890843","citation_count":45,"is_preprint":false},{"pmid":"10406465","id":"PMC_10406465","title":"Synergistic activation of the prolactin promoter by vitamin D receptor and GHF-1: role of the coactivators, CREB-binding protein and steroid hormone receptor coactivator-1 (SRC-1).","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10406465","citation_count":45,"is_preprint":false},{"pmid":"33714987","id":"PMC_33714987","title":"POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33714987","citation_count":43,"is_preprint":false},{"pmid":"10446901","id":"PMC_10446901","title":"A role for A/T-rich sequences and Pit-1/GHF-1 in a distal enhancer located in the human growth hormone locus control region with preferential pituitary activity in culture and transgenic mice.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10446901","citation_count":42,"is_preprint":false},{"pmid":"15998782","id":"PMC_15998782","title":"Functional relationship between LHX4 and POU1F1 in light of the LHX4 mutation identified in patients with pituitary defects.","date":"2005","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15998782","citation_count":41,"is_preprint":false},{"pmid":"11297581","id":"PMC_11297581","title":"Combined pituitary hormone deficiency caused by compound heterozygosity for two novel mutations in the POU domain of the Pit1/POU1F1 gene.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11297581","citation_count":39,"is_preprint":false},{"pmid":"7565785","id":"PMC_7565785","title":"Negative regulation of expression of the pituitary-specific transcription factor GHF-1/Pit-1 by thyroid hormones through interference with promoter enhancer elements.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565785","citation_count":38,"is_preprint":false},{"pmid":"1370379","id":"PMC_1370379","title":"Nucleotide sequence of the complementary DNA for human Pit-1/GHF-1.","date":"1992","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/1370379","citation_count":38,"is_preprint":false},{"pmid":"34270938","id":"PMC_34270938","title":"High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34270938","citation_count":36,"is_preprint":false},{"pmid":"1418622","id":"PMC_1418622","title":"Complementary DNA cloning and expression of Pit-1/GHF-1 from the domestic turkey.","date":"1992","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1418622","citation_count":34,"is_preprint":false},{"pmid":"31292963","id":"PMC_31292963","title":"POU1F1 transcription factor promotes breast cancer metastasis via recruitment and polarization of macrophages.","date":"2019","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31292963","citation_count":33,"is_preprint":false},{"pmid":"1634120","id":"PMC_1634120","title":"Structures of cDNAs encoding chum salmon pituitary-specific transcription factor, Pit-1/GHF-1.","date":"1992","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/1634120","citation_count":33,"is_preprint":false},{"pmid":"20389107","id":"PMC_20389107","title":"PROP1, HESX1, POU1F1, LHX3 and LHX4 mutation and deletion screening and GH1 P89L and IVS3+1/+2 mutation screening in a Dutch nationwide cohort of patients with combined pituitary hormone deficiency.","date":"2010","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20389107","citation_count":32,"is_preprint":false},{"pmid":"30934610","id":"PMC_30934610","title":"Relationship between SNPs of POU1F1 Gene and Litter Size and Growth Traits in Shaanbei White Cashmere Goats.","date":"2019","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/30934610","citation_count":30,"is_preprint":false},{"pmid":"26612202","id":"PMC_26612202","title":"Functional characterization of a human POU1F1 mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26612202","citation_count":30,"is_preprint":false},{"pmid":"9765286","id":"PMC_9765286","title":"Role of GHF-1 in the regulation of the rat growth hormone gene promoter by thyroid hormone and retinoic acid receptors.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9765286","citation_count":29,"is_preprint":false},{"pmid":"10319324","id":"PMC_10319324","title":"The tissue-specific transcription factor Pit-1/GHF-1 binds to the c-fos serum response element and activates c-fos transcription.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10319324","citation_count":29,"is_preprint":false},{"pmid":"9737723","id":"PMC_9737723","title":"A direct protein-protein interaction is involved in the cooperation between thyroid hormone and retinoic acid receptors and the transcription factor GHF-1.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9737723","citation_count":28,"is_preprint":false},{"pmid":"11927395","id":"PMC_11927395","title":"Pit-1/GHF-1 and GH expression in the MCF-7 human breast adenocarcinoma cell line.","date":"2002","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11927395","citation_count":27,"is_preprint":false},{"pmid":"8672234","id":"PMC_8672234","title":"Molecular cloning and characterization of the yellowtail GH gene and its promoter: a consensus sequence for teleost and avian Pit-1/GHF-1 binding sites.","date":"1996","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8672234","citation_count":26,"is_preprint":false},{"pmid":"7721104","id":"PMC_7721104","title":"A novel pituitary transcription factor is produced by alternative splicing of the human GHF-1/PIT-1 gene.","date":"1995","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7721104","citation_count":26,"is_preprint":false},{"pmid":"10514556","id":"PMC_10514556","title":"Changes in the levels of mRNAs for GH/prolactin/somatolactin family and Pit-1/GHF-1 in the pituitaries of pre-spawning chum salmon.","date":"1999","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10514556","citation_count":24,"is_preprint":false},{"pmid":"12932747","id":"PMC_12932747","title":"New N-terminal located mutation (Q4ter) within the POU1F1-gene (PIT-1) causes recessive combined pituitary hormone deficiency and variable phenotype.","date":"2003","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/12932747","citation_count":24,"is_preprint":false},{"pmid":"31226610","id":"PMC_31226610","title":"A novel missense mutation (L280V) within POU1F1 gene strongly affects litter size and growth traits in goat.","date":"2019","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/31226610","citation_count":23,"is_preprint":false},{"pmid":"16210857","id":"PMC_16210857","title":"Absent or delayed adrenarche in Pit-1/POU1F1 deficiency.","date":"2005","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/16210857","citation_count":22,"is_preprint":false},{"pmid":"8364038","id":"PMC_8364038","title":"Pit-1/GHF-1 binds to TRH-sensitive regions of the rat thyrotropin beta gene.","date":"1993","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8364038","citation_count":22,"is_preprint":false},{"pmid":"25500790","id":"PMC_25500790","title":"Molecular analysis of PROP1, POU1F1, LHX3, and HESX1 in Turkish patients with combined pituitary hormone deficiency: a multicenter study.","date":"2014","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/25500790","citation_count":22,"is_preprint":false},{"pmid":"7659093","id":"PMC_7659093","title":"Reconstitution of protein kinase A regulation of the rat prolactin promoter in HeLa nonpituitary cells: identification of both GHF-1/Pit-1-dependent and -independent mechanisms.","date":"1995","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7659093","citation_count":21,"is_preprint":false},{"pmid":"11812632","id":"PMC_11812632","title":"Neonatal Meishan pigs show POU1F1 genotype effects on plasma GH and PRL concentration.","date":"2002","source":"Animal reproduction science","url":"https://pubmed.ncbi.nlm.nih.gov/11812632","citation_count":21,"is_preprint":false},{"pmid":"27571135","id":"PMC_27571135","title":"A Sex-Dependent, Tropic Role for Leptin in the Somatotrope as a Regulator of POU1F1 and POU1F1-Dependent Hormones.","date":"2016","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27571135","citation_count":20,"is_preprint":false},{"pmid":"12904605","id":"PMC_12904605","title":"The de novo Q167K mutation in the POU1F1 gene leads to combined pituitary hormone deficiency in an Italian patient.","date":"2003","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/12904605","citation_count":20,"is_preprint":false},{"pmid":"25788520","id":"PMC_25788520","title":"FGFR2 regulates Mre11 expression and double-strand break repair via the MEK-ERK-POU1F1 pathway in breast tumorigenesis.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25788520","citation_count":19,"is_preprint":false},{"pmid":"15265078","id":"PMC_15265078","title":"A new single nucleotide polymorphism in the chicken pituitary-specific transcription factor (POU1F1) gene associated with growth rate.","date":"2004","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15265078","citation_count":19,"is_preprint":false},{"pmid":"27756091","id":"PMC_27756091","title":"Identification of Novel PROP1 and POU1F1 Mutations in Patients with Combined Pituitary Hormone Deficiency.","date":"2016","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/27756091","citation_count":18,"is_preprint":false},{"pmid":"11849139","id":"PMC_11849139","title":"Lack of association of GH1 and POU1F1 gene variants with meat production traits in Piemontese cattle.","date":"2002","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11849139","citation_count":18,"is_preprint":false},{"pmid":"7588287","id":"PMC_7588287","title":"Retinoic acid induces expression of the transcription factor GHF-1/Pit-1 in pituitary prolactin- and growth hormone-producing cell lines.","date":"1995","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7588287","citation_count":17,"is_preprint":false},{"pmid":"17941086","id":"PMC_17941086","title":"GHRH proliferative action on somatotrophs is cell-type specific and dependent on Pit-1/GHF-1 expression.","date":"2008","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17941086","citation_count":17,"is_preprint":false},{"pmid":"18059085","id":"PMC_18059085","title":"A novel germline mutation, IVS4+1G>A, of the POU1F1 gene underlying combined pituitary hormone deficiency.","date":"2007","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/18059085","citation_count":17,"is_preprint":false},{"pmid":"22010633","id":"PMC_22010633","title":"Two novel mutations in the POU1F1 gene generate null alleles through different mechanisms leading to combined pituitary hormone deficiency.","date":"2012","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22010633","citation_count":17,"is_preprint":false},{"pmid":"18654839","id":"PMC_18654839","title":"A PstI polymorphism at 3'UTR of goat POU1F1 gene and its effect on cashmere production.","date":"2008","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18654839","citation_count":16,"is_preprint":false},{"pmid":"17046590","id":"PMC_17046590","title":"Effect of genetic variations of the POU1F1 gene on growth traits of Nanyang cattle.","date":"2006","source":"Yi chuan xue bao = Acta genetica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/17046590","citation_count":16,"is_preprint":false},{"pmid":"23332017","id":"PMC_23332017","title":"POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15).","date":"2013","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23332017","citation_count":16,"is_preprint":false},{"pmid":"9714537","id":"PMC_9714537","title":"The LIM homeobox protein mLIM3/Lhx3 induces expression of the prolactin gene by a Pit-1/GHF-1-independent pathway in corticotroph AtT20 cells.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9714537","citation_count":15,"is_preprint":false},{"pmid":"27885216","id":"PMC_27885216","title":"A novel heterozygous intronic mutation in POU1F1 is associated with combined pituitary hormone deficiency.","date":"2016","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/27885216","citation_count":15,"is_preprint":false},{"pmid":"22311029","id":"PMC_22311029","title":"Analysis of polymorphism within POU1F1 gene in relation to milk production traits in dairy Sarda sheep breed.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22311029","citation_count":15,"is_preprint":false},{"pmid":"33373440","id":"PMC_33373440","title":"Control of the Anterior Pituitary Cell Lineage Regulator POU1F1 by the Stem Cell Determinant Musashi.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33373440","citation_count":14,"is_preprint":false},{"pmid":"18557974","id":"PMC_18557974","title":"A proline-to-histidine mutation in POU1F1 is associated with production traits in dairy cattle.","date":"2008","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18557974","citation_count":14,"is_preprint":false},{"pmid":"16968807","id":"PMC_16968807","title":"Identification and functional analysis of the novel S179R POU1F1 mutation associated with combined pituitary hormone deficiency.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16968807","citation_count":14,"is_preprint":false},{"pmid":"9817984","id":"PMC_9817984","title":"Anterior pituitary development and Pit-1/GHF-1 transcription factor.","date":"1998","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/9817984","citation_count":13,"is_preprint":false},{"pmid":"19808898","id":"PMC_19808898","title":"The Pit-1/Pou1f1 transcription factor regulates and correlates with prolactin expression in human breast cell lines and tumors.","date":"2010","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19808898","citation_count":13,"is_preprint":false},{"pmid":"16636924","id":"PMC_16636924","title":"Ovis aries POU1F1 gene: cloning, characterization and polymorphism analysis.","date":"2006","source":"Genetica","url":"https://pubmed.ncbi.nlm.nih.gov/16636924","citation_count":13,"is_preprint":false},{"pmid":"11589626","id":"PMC_11589626","title":"The turkey transcription factor Pit-1/GHF-1 can activate the turkey prolactin and growth hormone gene promoters in vitro but is not detectable in lactotrophs in vivo.","date":"2001","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11589626","citation_count":13,"is_preprint":false},{"pmid":"16942842","id":"PMC_16942842","title":"Identification and characterization of four splicing variants of ovine POU1F1 gene.","date":"2006","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16942842","citation_count":12,"is_preprint":false},{"pmid":"27175126","id":"PMC_27175126","title":"Polymorphism of sheep POU1F1 gene exon 6 and 3'UTR region and their association with milk production traits.","date":"2014","source":"Iranian journal of veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/27175126","citation_count":12,"is_preprint":false},{"pmid":"9034317","id":"PMC_9034317","title":"Molecular cloning of gilthead seabream (Sparus aurata) pituitary transcription factor GHF-1/Pit-1.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9034317","citation_count":11,"is_preprint":false},{"pmid":"32445923","id":"PMC_32445923","title":"ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32445923","citation_count":11,"is_preprint":false},{"pmid":"33261069","id":"PMC_33261069","title":"Proteomic and Transcriptomic Analysis Identify Spliceosome as a Significant Component of the Molecular Machinery in the Pituitary Tumors Derived from POU1F1- and NR5A1-Cell Lineages.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33261069","citation_count":11,"is_preprint":false},{"pmid":"21815258","id":"PMC_21815258","title":"Homozygous microdeletion of the POU1F1, CHMP2B, and VGLL3 genes in chromosome 3--a novel syndrome.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21815258","citation_count":11,"is_preprint":false},{"pmid":"22638072","id":"PMC_22638072","title":"Research resource: A genome-wide study identifies potential new target genes for POU1F1.","date":"2012","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22638072","citation_count":11,"is_preprint":false},{"pmid":"21521297","id":"PMC_21521297","title":"A novel POU1F1 mutation (p.Thr168IlefsX7) associated with an early and severe form of combined pituitary hormone deficiency: functional analysis and follow-up from infancy to adulthood.","date":"2011","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21521297","citation_count":11,"is_preprint":false},{"pmid":"30460459","id":"PMC_30460459","title":"Precocious or early puberty in patients with combined pituitary hormone deficiency due to POU1F1 gene mutation: case report and review of possible mechanisms.","date":"2018","source":"Hormones (Athens, Greece)","url":"https://pubmed.ncbi.nlm.nih.gov/30460459","citation_count":10,"is_preprint":false},{"pmid":"22722987","id":"PMC_22722987","title":"Polymorphisms and expression of the chicken POU1F1 gene associated with carcass traits.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22722987","citation_count":10,"is_preprint":false},{"pmid":"16110185","id":"PMC_16110185","title":"MspI polymorphisms in the 3rd intron of the swine POU1F1 gene and their associations with growth performance.","date":"2005","source":"Journal of applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16110185","citation_count":10,"is_preprint":false},{"pmid":"19498317","id":"PMC_19498317","title":"A novel recessive splicing mutation in the POU1F1 gene causing combined pituitary hormone deficiency.","date":"2009","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19498317","citation_count":10,"is_preprint":false},{"pmid":"21722153","id":"PMC_21722153","title":"Identification of a novel mutation in the exon 2 splice donor site of the POU1F1/PIT-1 gene in Japanese identical twins with mild combined pituitary hormone deficiency.","date":"2012","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21722153","citation_count":10,"is_preprint":false},{"pmid":"15844473","id":"PMC_15844473","title":"Three novel mutations in POU1F1 in Israeli patients with combined pituitary hormone deficiency.","date":"2005","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/15844473","citation_count":10,"is_preprint":false},{"pmid":"19370456","id":"PMC_19370456","title":"Associations of a HinfI PCR-RFLP of POU1F1 gene with growth traits in Qinchuan cattle.","date":"2009","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/19370456","citation_count":10,"is_preprint":false},{"pmid":"35951005","id":"PMC_35951005","title":"Heterozygous variants in SIX3 and POU1F1 cause pituitary hormone deficiency in mouse and man.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35951005","citation_count":9,"is_preprint":false},{"pmid":"28013048","id":"PMC_28013048","title":"Pou1f1, the key transcription factor related to somatic growth in tilapia (Orechromis niloticus), is regulated by two independent post-transcriptional regulation mechanisms.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28013048","citation_count":9,"is_preprint":false},{"pmid":"11370678","id":"PMC_11370678","title":"Cloning of the full length pig PIT1 (POU1F1) CDNA and a novel alternative PIT1 transcript, and functional studies of their encoded proteins.","date":"2001","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/11370678","citation_count":9,"is_preprint":false},{"pmid":"33886498","id":"PMC_33886498","title":"A mutation of the β-domain in POU1F1 causes pituitary deficiency due to dominant PIT-1β expression.","date":"2021","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33886498","citation_count":8,"is_preprint":false},{"pmid":"21787958","id":"PMC_21787958","title":"Short communication: expression and alternative splicing of POU1F1 pathway genes in preimplantation bovine embryos.","date":"2011","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/21787958","citation_count":8,"is_preprint":false},{"pmid":"33742319","id":"PMC_33742319","title":"POU1F1 mutations in combined pituitary hormone deficiency: differing spectrum of mutations in a Western-Indian cohort and systematic analysis of world literature.","date":"2021","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/33742319","citation_count":8,"is_preprint":false},{"pmid":"21769479","id":"PMC_21769479","title":"Polymorphisms of caprine POU1F1 gene and their association with litter size in Jining Grey goats.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21769479","citation_count":8,"is_preprint":false},{"pmid":"33550451","id":"PMC_33550451","title":"Intronic variant in POU1F1 associated with canine pituitary dwarfism.","date":"2021","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33550451","citation_count":7,"is_preprint":false},{"pmid":"19608642","id":"PMC_19608642","title":"Expression of the synaptotagmin I gene is enhanced by binding of the pituitary-specific transcription factor, POU1F1.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19608642","citation_count":7,"is_preprint":false},{"pmid":"21316014","id":"PMC_21316014","title":"Congenital hypopituitarism due to POU1F1 gene mutation.","date":"2011","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/21316014","citation_count":7,"is_preprint":false},{"pmid":"17998594","id":"PMC_17998594","title":"Polymorphisms in intron 1 of the porcine POU1F1 gene.","date":"2007","source":"Journal of applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17998594","citation_count":7,"is_preprint":false},{"pmid":"23184007","id":"PMC_23184007","title":"Identification of novel SNPs in the Sarda breed goats POU1F1 gene and their association with milk productive performance.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23184007","citation_count":7,"is_preprint":false},{"pmid":"22094313","id":"PMC_22094313","title":"POU1F1-mediated activation of hGH-N by deoxyribonuclease I hypersensitive site II of the human growth hormone locus control region.","date":"2011","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22094313","citation_count":7,"is_preprint":false},{"pmid":"36427334","id":"PMC_36427334","title":"POU1F1/Pou1f1 c.143-83A > G Variant Disrupts the Branch Site in Pre-mRNA and Leads to Dwarfism.","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36427334","citation_count":6,"is_preprint":false},{"pmid":"31022740","id":"PMC_31022740","title":"Characterization of a Novel POU1F1 Mutation Identified on Screening 160 Growth Hormone Deficiency Patients.","date":"2019","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/31022740","citation_count":6,"is_preprint":false},{"pmid":"34815942","id":"PMC_34815942","title":"Congenital hypopituitarism due to novel compound heterozygous POU1F1 gene mutation: A case report and review of the literature.","date":"2021","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/34815942","citation_count":6,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50858,"output_tokens":9268,"usd":0.145797,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19107,"output_tokens":4068,"usd":0.098617,"stage2_stop_reason":"end_turn"},"total_usd":0.244414,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"GHF-1 (POU1F1) is a homeobox-containing protein; the homeodomain region near its C-terminus functions as its DNA-binding domain, demonstrated by DNase I footprinting with bacterially expressed GHF-1 fusion protein.\",\n      \"method\": \"cDNA cloning, sequence analysis, DNase I footprinting with bacterially expressed fusion protein\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro biochemical reconstitution (footprinting with recombinant protein), foundational study replicated widely\",\n      \"pmids\": [\"2902927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The GHF-1/POU1F1 homeodomain is sufficient for sequence-specific DNA binding; the POU-specific domain stimulates DNA binding but does not contact DNA directly; transcriptional activation is mediated by a separate hydroxylated amino-acid-rich domain.\",\n      \"method\": \"Domain deletion/truncation analysis, in vitro transcription, DNA-binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple domain dissection experiments with functional readouts in a single rigorous study\",\n      \"pmids\": [\"2574416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Purified GHF-1/POU1F1 (33 kDa) binds to and activates the GH promoter but does not recognize the prolactin (Prl) promoter; a distinct factor in the same extracts binds the Prl promoter.\",\n      \"method\": \"Protein purification, gel-shift assay, in vitro transcription, immunoblotting\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purified native protein used in multiple in vitro assays\",\n      \"pmids\": [\"2563596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Extinction of GH expression in fibroblast × pituitary cell hybrids occurs via repression of GHF-1/POU1F1 protein and mRNA, not via a direct repressor of the GH promoter.\",\n      \"method\": \"Somatic cell hybridization, in vivo transfection, in vitro transcription, DNase I footprinting, immunoblotting\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, epistasis-like genetic experiment with clear mechanism\",\n      \"pmids\": [\"3167985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"POU1F1/Pit-1 binds to and activates cell-specific elements in both the GH and PRL gene promoters; 31 and 33 kDa nuclear proteins recognized by a Pit-1/GHF-1 antibody bind these elements in pituitary cells; cotransfection of RSV-Pit-1/GHF-1 into non-pituitary HeLa cells reconstitutes activation of both promoters.\",\n      \"method\": \"Protein-DNA binding assays, cotransfection/reporter assay, immunoblotting with Pit-1 antibody\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding and functional reconstitution in non-pituitary cells, multiple orthogonal methods\",\n      \"pmids\": [\"2284007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Sp1 binding to its site on the human GH promoter is mutually exclusive with GHF-1 binding to its distal site (demonstrated by DNase I footprinting), and Sp1 can partially compensate for low GHF-1 concentrations in stimulating transcription.\",\n      \"method\": \"DNase I footprinting, cell-free transcription assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro assays but single lab, limited functional follow-up\",\n      \"pmids\": [\"2181288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"POU1F1/Pit-1 (or a closely related protein) mediates TRH responsiveness of the human TSHβ (TSHB) gene via a binding site at -128 to -92 bp; demonstrated by DNase I footprinting with thyrotropic tumor extract and transfection studies with an N-terminal deletion of Pit-1/GHF-1.\",\n      \"method\": \"DNase I footprinting, deletion analysis, transient transfection with reporter gene\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNase I footprinting plus functional transfection, single lab\",\n      \"pmids\": [\"1901656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"GHF-1/POU1F1 is required for generation of somatotropes and lactotropes and for GH and PRL gene expression during pituitary development; immortalization of GHF-1-expressing progenitors that lack GH/PRL results in dwarfism, and an early-acting GHF-1 transcriptional enhancer was identified in this progenitor context.\",\n      \"method\": \"Transgenic mouse model (GHF-1 promoter driving SV40 T-antigen), cell line derivation, functional enhancer assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic loss-of-function with clear developmental phenotype, replicated in derived cell lines\",\n      \"pmids\": [\"8096199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"POU1F1/Pit-1 binds to three A-T-rich regions (TSH A, B, C) in the 5'-flanking region of the rat TSHβ gene; TSH A and TSH C each confer TRH-stimulated and/or enhanced basal activity to a heterologous promoter, and all three elements bind in vitro-translated Pit-1 with defined affinities.\",\n      \"method\": \"Gel mobility shift assay with antibody supershift, transient transfection reporter assay, in vitro translated protein binding\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding with recombinant protein plus functional reporter assay, single lab\",\n      \"pmids\": [\"8364038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GHF-1/POU1F1 undergoes M-phase-specific phosphorylation at Thr-220 (within the N-terminal arm of the homeodomain) by a novel mitotic kinase activity distinct from Cdc2 or PKA, transiently inhibiting its DNA-binding activity during mitosis; PKA does not phosphorylate this inhibitory site in living cells.\",\n      \"method\": \"In vivo phosphorylation analysis, in vitro kinase assays, site-directed mutagenesis, cell synchronization, DNA-binding assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay combined with mutagenesis and DNA-binding readout, multiple methods\",\n      \"pmids\": [\"8524234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GHF-1/POU1F1 and PKA synergistically activate the rat PRL promoter via the FP I site; GHF-1 is necessary but not sufficient for the full PKA response, which also requires a GHF-1-independent ubiquitous factor acting at FP I.\",\n      \"method\": \"Cotransfection reconstitution assay in HeLa cells with expression vectors, site-specific mutagenesis, luciferase reporter\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution in non-pituitary cells with site-directed mutations, single lab\",\n      \"pmids\": [\"7659093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"GHRH increases GHF-1/POU1F1 mRNA levels via a transcriptional mechanism not requiring new protein synthesis; IGF-1 inhibits basal GHF-1 mRNA and blocks GHRH induction; somatostatin has no effect.\",\n      \"method\": \"Primary anterior pituitary cell culture, Northern blotting, actinomycin D and cycloheximide treatments, pharmacological activation of second messengers\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with transcription inhibitors, multiple hormone treatments, single lab\",\n      \"pmids\": [\"7649093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Retinoic acid induces GHF-1/POU1F1 mRNA and protein expression in pituitary cell lines via sequences between -400 and -90 bp of the GHF-1/Pit-1 promoter containing two CREs, both of which are required; T3 decreases GHF-1 mRNA and promoter activity in GH4C1 cells and blocks RA stimulation.\",\n      \"method\": \"Northern blotting, Western blotting, gel retardation assay, promoter-reporter transfection with deletion constructs\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (Northern, Western, EMSA, reporter), single lab\",\n      \"pmids\": [\"7588287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"T3 represses GHF-1/POU1F1 gene expression by transcriptional interference with CRE-containing promoter elements (bp -90 to -200), not through a canonical TRE, and also interferes with GHF-1 binding to a positive autoregulatory element at bp -45 to -63.\",\n      \"method\": \"Promoter-reporter transfection with deletion constructs, in vitro DNA-binding assay, RT-PCR/Northern\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion mapping with functional reporter plus in vitro binding, single lab\",\n      \"pmids\": [\"7565785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"POU1F1/GHF-1 functions as a cell-specific integrator of Ras signaling by forming a composite binding site with Ets-1 at positions -217 to -190 of the rat PRL promoter; both Ets-1 and GHF-1 binding sites are required for Ras/Raf activation; the composite element confers Ras responsiveness when inserted into the GH promoter.\",\n      \"method\": \"Site-directed mutagenesis of promoter, luciferase reporter assay, EMSA, insertion of composite element into heterologous promoter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (mutagenesis, reporter, EMSA, element transfer), functional epistasis\",\n      \"pmids\": [\"8798730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"GHF-1/POU1F1 physically interacts with RXR (strong), RAR (weak), and TR (weak) via in vitro GST pull-down; GHF-1 and TR/RXR or RAR/RXR heterodimers form a ternary complex with the GH promoter fragment, and GHF-1 increases receptor binding to the promoter under limiting conditions.\",\n      \"method\": \"GST pull-down (in vitro binding), EMSA (ternary complex), reporter assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GST pull-down plus EMSA ternary complex, single lab\",\n      \"pmids\": [\"9737723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In pituitary cells, GHF-1/POU1F1 converts T3/RA receptor-mediated repression into ligand-dependent activation of the GH promoter; a truncated T3 receptor lacking N-terminus and DNA-binding domain still activates the GH promoter in the presence of GHF-1 and RXR, indicating protein-protein interaction is sufficient.\",\n      \"method\": \"Transient transfection reporter assay in HeLa cells with/without GHF-1, GH promoter activity measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution with domain-deleted receptors, single lab\",\n      \"pmids\": [\"9765286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"VDR and GHF-1/Pit-1 synergistically activate the PRL promoter; coactivators CBP and SRC-1 enhance VDR-mediated activation via the AF-2 domain; CBP also enhances GHF-1-mediated activation of the PRL promoter.\",\n      \"method\": \"Transient transfection reporter assay in HeLa cells, cotransfection with VDR, GHF-1, SRC-1, and CBP expression vectors, AF-2 mutant analysis\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reconstitution in non-pituitary cells with multiple cofactors, single lab\",\n      \"pmids\": [\"10406465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"POU1F1/Pit-1 directly binds the serum response element (SRE) in the c-fos promoter (albeit with lower affinity than its cognate site) and activates c-fos transcription in a phosphorylation-dependent manner; Pit-1 phosphorylation sites are required for c-fos promoter activity but not for hormonal gene regulation.\",\n      \"method\": \"Gel shift analysis, overexpression in PC12 cells, antisense-mediated knockdown in GH3 cells, reporter assay with mutant Pit-1 phosphorylation sites\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus loss-of-function knockdown plus reporter assay, single lab\",\n      \"pmids\": [\"10319324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"POU1F1/Pit-1 binds A/T-rich sequences within a 203-bp enhancer element of the human GH locus control region (LCR) HSII region and is required for enhancer activity in pituitary cells in culture and in transgenic mice.\",\n      \"method\": \"EMSA (competition and antibody supershift with recombinant protein), deletion analysis, promoter-reporter transfection, transgenic mouse reporter\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding with recombinant protein, functional validation both in culture and in vivo (transgenic mice)\",\n      \"pmids\": [\"10446901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"POU1F1 mutation E230K reduces transactivation but not DNA-binding affinity; R172Q reduces both DNA binding and transactivation; ins778A abolishes DNA binding and reduces transactivation — demonstrating mutation-specific functional defects in the context of CPHD.\",\n      \"method\": \"Functional studies: transactivation reporter assay, DNA-binding affinity assay (EMSA or similar)\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal functional assays (DNA binding + transactivation) per mutation, single lab\",\n      \"pmids\": [\"15928241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LHX4 binds to a human-specific element in the POU1F1 upstream regulatory sequence and activates POU1F1 transcription; mutant LHX4 proteins from CPHD patients fail to bind and activate the POU1F1 regulatory sequence but do not act as dominant negatives over normal LHX4.\",\n      \"method\": \"Recombinant protein expression in CHO cells, DNA-binding assay, reporter/transactivation assay\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding and transactivation assays, single lab, single cell system\",\n      \"pmids\": [\"15998782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"OTX2 binds to target sequences within the POU1F1 promoter and markedly transactivates it (~19-fold); a frameshift OTX2 mutation retaining the homeodomain but losing the transactivation domain barely retains this activity with no dominant-negative effect.\",\n      \"method\": \"Transfection reporter (luciferase) assay, nuclear localization assay, OTX2 wild-type vs. mutant comparison\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay with mutant comparison, single lab\",\n      \"pmids\": [\"18628516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"POU1F1 mutation S179R (in the POU-specific domain) abolishes interaction with coactivator CBP on the PRL promoter (but not with LHX3) and markedly reduces DNA binding and transactivation, with normal nuclear accumulation.\",\n      \"method\": \"Transactivation reporter assay, EMSA (DNA binding), nuclear accumulation assay, functional interaction studies in alphaT3 cells\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (EMSA, reporter, cofactor interaction), single lab\",\n      \"pmids\": [\"16968807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"POU1F1 proliferative response to GHRH is cell-type specific and requires Pit-1/GHF-1 expression; Pit-1 is needed for downstream GHRH receptor signaling effects on cell proliferation (p27 degradation), demonstrated by Pit-1 siRNA knockdown in GH3-GHRHR cells and by exogenous Pit-1 expression in CHO-4 cells.\",\n      \"method\": \"siRNA knockdown, overexpression, cell proliferation assays, Western blotting for cell cycle regulators\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal loss- and gain-of-function in two cell types, single lab\",\n      \"pmids\": [\"17941086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"POU1F1 binds directly to a site near the Syt1 (synaptotagmin I) initiation exon in GH3 pituitary cells (ChIP, in vitro binding), and POU1F1 knockdown reduces endogenous Syt1 mRNA; luciferase reporter assays confirm a POU1F1-regulated internal Syt1 promoter.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), shRNA knockdown, in vitro DNA binding, luciferase reporter transfection\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus knockdown plus reporter assay, multiple methods, single lab\",\n      \"pmids\": [\"19608642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IGF-1 inhibits GH gene expression by disrupting the POU1F1/CBP complex at the GH promoter; IGF-1 receptor signaling prevents CBP binding to the GH promoter (shown by ChIP), and a CBP S436A phosphorylation-dead mutant abolishes IGF-1 inhibition, elevating serum GH in knock-in mice.\",\n      \"method\": \"ChIP assay, luciferase reporter, CBP mutant (S436A) knock-in mouse model, serum GH/GHRH stimulation assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, mutagenesis, and in vivo knock-in mouse validation — multiple orthogonal methods\",\n      \"pmids\": [\"22890843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"POU1F1 directly binds multiple sites at the HSII region of the hGH LCR, confers robust POU1F1-dependent activation of hGH-N in a minichromosome model, and is required for POU1F1-dependent histone acetylation and methylation throughout the LCR/hGH-N domain; one binding site maps to the 3' UTR of a primate-specific LINE-1 retrotransposon.\",\n      \"method\": \"Minichromosome reporter system, in vitro DNA binding, ChIP for histone modifications, transfection assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel chromatin system with multiple binding and ChIP experiments, single lab\",\n      \"pmids\": [\"22094313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"POU1F1 Pro76Leu mutation (in the transactivation domain) selectively alters DNA-binding affinity at hGH-LCR and hGH1 sites (but not PRL sites), enhances interactions with cofactors PITX1, LHX3a, and ELK1 (by Co-IP), and causes dramatic loss of protein expression in homozygous knock-in mice despite normal mRNA levels.\",\n      \"method\": \"Bandshift (EMSA) assay, Co-immunoprecipitation, knock-in mouse model, immunoblotting\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (EMSA, Co-IP, in vivo knock-in), single lab but rigorous\",\n      \"pmids\": [\"26612202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK (downstream of FGFR2) directly interacts with and phosphorylates POU1F1, increasing POU1F1 binding to the Mre11 promoter and repressing Mre11 expression, thereby decreasing double-strand break repair in breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assay, ChIP on Mre11 promoter, reporter assay, shRNA knockdown\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus reporter assay, single lab\",\n      \"pmids\": [\"25788520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"POU1F1 (Pit-1) in breast tumor cells drives recruitment and M2 polarization of macrophages via transcriptional regulation of CXCL12 secretion; TAMs in turn promote tumor growth, angiogenesis, and lung metastasis.\",\n      \"method\": \"In vitro co-culture, zebrafish and mouse xenograft models, CXCL12 measurement, flow cytometry for macrophage markers, shRNA knockdown of POU1F1\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in multiple in vivo models with mechanistic pathway (CXCL12/CXCR4), single lab\",\n      \"pmids\": [\"31292963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"POU1F1 mediates ADTRP-induced transcription of TFPI by binding to a 50-bp ADTRP-response element (-806 to -756 bp upstream of TFPI TSS); knockdown of POU1F1 abolishes ADTRP-mediated TFPI transcription; direct binding confirmed by ChIP and EMSA.\",\n      \"method\": \"Luciferase reporter assay (large/small deletions), ChIP, EMSA, siRNA knockdown\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus EMSA plus reporter plus knockdown, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"32445923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"POU1F1 transcriptionally regulates the LDHA gene in breast cancer cells; POU1F1 overexpression increases LDHA expression and lactate production, promoting glycolytic reprogramming; LDHA knockdown in POU1F1-overexpressing cells reduces tumor volume and [18F]FDG uptake in xenograft mice.\",\n      \"method\": \"shRNA knockdown, overexpression, luciferase reporter, xenograft mouse model with PET imaging, human primary cancer cell cultures\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter plus in vivo xenograft validation, multiple methods, single lab\",\n      \"pmids\": [\"33714987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HMGA1B/2 transcriptionally activates POU1F1 in gastric cancer; POU1F1 in turn promotes CXCL12/CXCR4-dependent macrophage polarization; GST pull-down and Co-IP confirmed physical interaction between HMGA1B/2 and POU1F1; ChIP and dual luciferase assays confirmed HMGA1B/2 transcriptional regulation of POU1F1.\",\n      \"method\": \"GST pull-down, Co-immunoprecipitation, ChIP, dual luciferase reporter assay, xenograft mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (GST pull-down, Co-IP, ChIP, reporter), single lab\",\n      \"pmids\": [\"33927188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The stem cell RNA-binding protein Musashi1 directly binds the Pou1f1 mRNA 3' UTR and exerts translational repression of POU1F1 in female somatotropes; leptin signaling is required to relieve this repression; Musashi immunoprecipitation from whole pituitary co-purifies Pou1f1 mRNA.\",\n      \"method\": \"RNA immunoprecipitation, translational reporter assay, Cre-LoxP Lepr-null somatotrope purification, immunocytochemistry, single-cell RNA-seq\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA IP plus functional reporter plus genetic model, multiple methods, single lab\",\n      \"pmids\": [\"33373440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Heterozygous missense POU1F1 variants that affect only the POU1F1 beta isoform retain repressor activity and shift splicing to favor the beta isoform, causing dominant-negative loss of function; identified by high-throughput splicing reporter assay testing 1,070 SNVs.\",\n      \"method\": \"High-throughput splicing reporter assay (1,070 variants), functional repressor activity assay, clinical co-segregation in multiple families\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — large-scale systematic splicing assay plus functional validation, replicated across multiple unrelated families\",\n      \"pmids\": [\"34270938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A POU1F1 intronic variant (c.143-69T>G in intron 1 of PIT-1α) shifts splicing to produce exclusively the PIT-1β transcript; the PIT-1β-Ile51Ser mutant protein represses PIT-1α transcriptional activity and abolishes transactivation of the rat PRL promoter in GH3 cells, causing CPHD.\",\n      \"method\": \"Gene splicing experiments, luciferase reporter assay, lymphocyte mRNA expression analysis\",\n      \"journal\": \"European journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — splicing assay plus functional reporter in pituitary cells, single lab\",\n      \"pmids\": [\"33886498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The intronic Pou1f1 variant c.143-83A>G disrupts a branch site in the pre-mRNA, shifting splicing to decrease the alpha isoform, increase the beta isoform, and produce an exon-skipped transcript; homozygous knock-in mice show pituitary hypoplasia, somatotroph reduction, dwarfism, and IGF-1/T4 deficiency.\",\n      \"method\": \"Knock-in mouse model (CRISPR/genome engineering), RNA-seq, RT-PCR, immunohistochemistry, splicing analysis in cultured cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knock-in model with RNA-seq, histology, and cell-based splicing assays confirming mechanism\",\n      \"pmids\": [\"36427334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Leptin signaling to somatotropes is required to maintain POU1F1 protein levels and all POU1F1-dependent hormones (GH, PRL, TSH); reduction is sex-dependent (occurs in females but not males for TSH and PRL), demonstrating a tropic role for leptin in controlling POU1F1-dependent cell lineages.\",\n      \"method\": \"Cre-LoxP conditional Lepr knockout in somatotropes, FACS-purified cell populations, enzyme immunoassays, qPCR\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional knockout with purified somatotropes, functional hormone measurements, single lab\",\n      \"pmids\": [\"27571135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"POU1F1 W193R missense mutation (in the fourth alpha-helix of the POU-specific domain) causes a ~500-fold reduction in DNA binding and transcriptional activation; a frameshift (747delA) removes the entire DNA recognition helix of the homeodomain, producing a nonfunctional protein.\",\n      \"method\": \"DNA-binding assay, transactivation reporter assay, cell transfection\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative DNA-binding plus reporter assay for two mutations, single lab\",\n      \"pmids\": [\"11297581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Genetic epistasis between Pou1f1 and Six3 in mice: Six3 heterozygotes have pituitary dysmorphology; Six3+/-; Pou1f1+/dw double heterozygotes have a pronounced pituitary phenotype including pituitary growth through the palate, supporting digenic pituitary disease.\",\n      \"method\": \"Genetically engineered double-heterozygous mice, pituitary histology, phenotypic analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with defined phenotype, single lab but clear digenic interaction\",\n      \"pmids\": [\"35951005\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"POU1F1 (GHF-1/Pit-1) is a pituitary-specific POU-homeodomain transcription factor whose homeodomain mediates sequence-specific DNA binding (stimulated by the POU-specific domain), while a separate hydroxylated amino-acid-rich domain drives transcriptional activation; it directly activates GH, PRL, and TSHβ gene promoters, autoregulates its own promoter, and is required for the specification and expansion of somatotrope, lactotrope, and thyrotrope lineages; its activity is regulated by M-phase-specific phosphorylation at Thr-220 that transiently inhibits DNA binding, by IGF-1 receptor signaling that disrupts its interaction with the coactivator CBP, by Musashi1-mediated translational repression of its mRNA (reversed by leptin), and by alternative splicing that produces a repressive beta isoform; it integrates upstream signals (GHRH/cAMP/Ras via Ets-1, thyroid hormone and retinoic acid receptors via physical interaction, LHX4 and OTX2 upstream activation) and in cancer contexts transcriptionally activates LDHA and CXCL12 to promote metabolic reprogramming and macrophage polarization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"POU1F1 (GHF-1/Pit-1) is a pituitary-specific POU-homeodomain transcription factor that specifies and expands the somatotrope, lactotrope, and thyrotrope lineages and directly drives their hormone gene programs [#7]. Its C-terminal homeodomain is sufficient for sequence-specific DNA binding while the POU-specific domain stimulates that binding without contacting DNA directly, and transcriptional activation is carried by a separate hydroxylated amino-acid-rich domain [#0, #1]. The factor binds and activates cell-specific elements of the GH and PRL promoters — reconstituting their activation when introduced into non-pituitary cells [#2, #4] — and binds A-T-rich elements of the TSHβ gene to confer TRH responsiveness [#6, #8]. At the human GH locus it occupies multiple sites in the locus control region HSII enhancer and is required for POU1F1-dependent histone acetylation/methylation and high-level hGH-N expression [#19, #27]. POU1F1 also acts as a signal integrator: it forms a composite element with Ets-1 to confer Ras responsiveness [#14], cooperates with nuclear hormone receptors (RXR/RAR/TR, VDR) through direct interaction and ternary-complex formation on target promoters [#15, #16, #17], and recruits the coactivator CBP, an interaction disrupted by IGF-1 receptor signaling to inhibit GH expression [#23, #26]. Its activity is gated by M-phase-specific phosphorylation at Thr-220 that transiently inhibits DNA binding [#9], by Musashi1-mediated translational repression of its mRNA that is relieved by leptin signaling [#34, #38], and by alternative splicing that generates a repressive beta isoform [#35, #36]. Loss-of-function and dominant-negative POU1F1 variants — affecting DNA binding, transactivation, cofactor interaction, or splicing — cause combined pituitary hormone deficiency [#20, #23, #35, #37, #39]. In cancer contexts POU1F1 transcriptionally activates LDHA to drive glycolytic reprogramming and CXCL12 to recruit and M2-polarize macrophages, promoting tumor growth and metastasis [#30, #32].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Establishing how DNA recognition and activation are partitioned within the protein defined POU1F1 as a modular POU-homeodomain factor.\",\n      \"evidence\": \"cDNA cloning, DNase I footprinting with recombinant protein, and domain deletion/truncation with in vitro transcription readouts\",\n      \"pmids\": [\"2902927\", \"2574416\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of the DNA-bound complex\", \"Role of the POU-specific domain in stimulating binding defined functionally but not structurally\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating direct binding and reconstituted activation of GH and PRL promoters established POU1F1 as the cell-specific activator of these hormone genes.\",\n      \"evidence\": \"Protein purification, gel-shift, in vitro transcription, and cotransfection reconstitution in non-pituitary HeLa cells\",\n      \"pmids\": [\"2563596\", \"2284007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Early purified protein did not bind PRL promoter, later resolved by reconstitution\", \"Did not address chromatin context of native loci\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Resolving whether POU1F1 is required for lineage formation versus only hormone transcription showed it is needed for somatotrope/lactotrope generation in vivo.\",\n      \"evidence\": \"Transgenic mouse with GHF-1 promoter driving SV40 T-antigen, derived progenitor cell lines, and enhancer assay\",\n      \"pmids\": [\"8096199\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the upstream specification cascade\", \"Mechanism of lineage expansion versus maintenance not separated\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping A-T-rich TSHβ elements extended POU1F1's direct target repertoire to thyrotrope hormone genes and TRH responsiveness.\",\n      \"evidence\": \"Gel-shift with antibody supershift, in vitro-translated protein binding, and transfection reporter assays on rat/human TSHβ\",\n      \"pmids\": [\"1901656\", \"8364038\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TRH signaling link to POU1F1 occupancy not mechanistically resolved\", \"Relative contributions of the three elements in vivo unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showing POU1F1 forms a composite Ets-1 element established it as a cell-specific integrator of Ras/Raf signaling.\",\n      \"evidence\": \"Promoter mutagenesis, luciferase reporter, EMSA, and transfer of the composite element to a heterologous promoter\",\n      \"pmids\": [\"8798730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct POU1F1-Ets-1 contact not biochemically mapped\", \"Other Ras-responsive POU1F1 targets not catalogued\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating physical interaction with nuclear hormone receptors explained how POU1F1 converts receptor-mediated repression into ligand-dependent GH activation.\",\n      \"evidence\": \"GST pull-down, ternary-complex EMSA, and reporter assays with domain-deleted receptors in pituitary and HeLa cells\",\n      \"pmids\": [\"9737723\", \"9765286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction surfaces not mapped at residue level\", \"In vivo relevance to physiological GH regulation not tested\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying M-phase Thr-220 phosphorylation revealed cell-cycle gating of POU1F1 DNA binding by a non-Cdc2/non-PKA mitotic kinase.\",\n      \"evidence\": \"In vivo and in vitro kinase assays, site-directed mutagenesis, cell synchronization, and DNA-binding readouts\",\n      \"pmids\": [\"8524234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the mitotic kinase unknown\", \"Consequence for hormone gene output across the cycle not quantified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Tracing IGF-1 inhibition to disruption of the POU1F1/CBP complex provided a coactivator-level mechanism for negative feedback on GH.\",\n      \"evidence\": \"ChIP, luciferase reporter, and a CBP S436A phospho-dead knock-in mouse with serum GH measurement\",\n      \"pmids\": [\"22890843\", \"16968807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase phosphorylating CBP S436 downstream of IGF-1R not defined here\", \"Whether other coactivators substitute is unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying LHX4 and OTX2 as direct activators of the POU1F1 promoter placed POU1F1 within an upstream transcriptional hierarchy of pituitary development.\",\n      \"evidence\": \"Recombinant binding and transactivation reporter assays comparing wild-type versus CPHD-patient mutant LHX4/OTX2\",\n      \"pmids\": [\"15998782\", \"18628516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Combinatorial regulation of the POU1F1 promoter not resolved\", \"Some regulatory elements are human-specific, limiting cross-species inference\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing Musashi1 translationally represses Pou1f1 mRNA, reversibly via leptin, revealed a post-transcriptional and metabolic control layer over POU1F1 abundance.\",\n      \"evidence\": \"RNA immunoprecipitation, translational reporter, leptin receptor conditional knockout, and somatotrope purification\",\n      \"pmids\": [\"33373440\", \"27571135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Sex-dependence of leptin control mechanistically unexplained\", \"Other RBPs acting on Pou1f1 mRNA not surveyed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Systematic splicing variant assays and knock-in models established that shifting the alpha/beta isoform balance toward a repressive beta isoform causes dominant-negative CPHD.\",\n      \"evidence\": \"High-throughput splicing reporter (1,070 SNVs), repressor activity assays, multi-family co-segregation, and CRISPR knock-in mice\",\n      \"pmids\": [\"34270938\", \"33886498\", \"36427334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Beta-isoform target genes and repression mechanism not fully defined\", \"Tissue-specific splicing regulators controlling the alpha/beta ratio unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defining POU1F1 targets in tumor cells (LDHA, CXCL12, Mre11) showed it drives metabolic reprogramming, immune microenvironment remodeling, and altered DNA repair outside the pituitary.\",\n      \"evidence\": \"shRNA/overexpression, ChIP, reporter assays, Co-IP with ERK/HMGA, and xenograft/zebrafish models with PET imaging and macrophage profiling\",\n      \"pmids\": [\"33714987\", \"31292963\", \"25788520\", \"33927188\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"What activates POU1F1 in non-pituitary tumors only partially defined (HMGA1B/2, FGFR2/ERK)\", \"Direct versus indirect status of some cancer targets not fully separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse POU1F1 control layers — mitotic phosphorylation, coactivator switching, translational repression, and alpha/beta splicing — are coordinated in vivo to set lineage-specific hormone output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated model linking the regulatory inputs\", \"Identity of the M-phase kinase and the beta-isoform repressive program still open\", \"Structural basis of DNA and cofactor recognition not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 4, 7, 14, 32]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 8, 19, 39]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 4, 7, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 21, 22, 40]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 26, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CREBBP\", \"ETS1\", \"RXR\", \"TR\", \"VDR\", \"LHX3\", \"PITX1\", \"ELK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}